Yvette Drew

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Rucaparib Maintenance Treatment, Medicine, Recurrent Ovarian Carcinoma +7

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey et al. · The Lancet Oncology · 2020 · 599 citations · Full text

Primary Tumour Subtype, Epidemiology, Cancer Epidemiology +11

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Asima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite et al. · Clinical Cancer Research · 2010 · 267 citations · Full text

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

Yvette Drew, Evan A. Mulligan, Wan-Tse Vong et al. · JNCI Journal of the National Cancer Institute · 2010 · 257 citations · Full text

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris et al. · Clinical Cancer Research · 2017 · 236 citations